Why Cell Therapy Visibility Must Start at Patient Enrollment – Not Manufacturing
In many cell therapy programs, visibility is often viewed as a manufacturing responsibility. Where is the batch? Which step is currently active? Has quality review been completed? These are valid and necessary questions. Manufacturing visibility remains a foundational requirement for maintaining FDA compliance, supporting GMP environments, and aligning with validated Standard Operating Procedures (SOPs). But over time, many organizations have begun to notice something important: Manufacturing visibility alone does not provide the full picture. Cell therapy is fundamentally different from traditional pharmaceutical manufacturing. It is not batch-first manufacturing. It is patient-first manufacturing. And the patient journey begins long before the …
How to Digitize Your SOPs Without Disrupting FDA-Validated Processes
In the fast-evolving world of cell and gene therapy, operational efficiency is more than a business goal, it’s a patient safety imperative. Yet, for many CDMOs, CMOs, and biotech companies, the idea of digitizing Standard Operating Procedures (SOPs) triggers a common concern: “What if we disrupt what’s already FDA-validated?” The Challenge Manual SOP management remains the norm in many facilities. Paper binders, siloed spreadsheets, and inconsistent updates can create delays, increase the risk of errors, and complicate audits. While digitization promises efficiency and enhanced traceability, the fear of invalidating FDA approvals often slows progress. Consider this: an operator spends 20–30 …
